Background
Progressive multifocal leukoencephalopathy (PML) caused by JC virus (JCV) is a rare but serious complication of some disease-modifying drugs used to treat multiple sclerosis (MS). Japanese MS patients treated with fingolimod were reported to be 10 times more likely to develop PML than equivalent patients in other countries. The strongest susceptibility
human leukocyte antigen
(
HLA
) class II alleles for MS are distinct between races (
DRB1*15:01
for Caucasians and
DRB1*04:05
and
DRB1*15:01
for Japanese); therefore, we investigated whether
HLA
class II alleles modulate anti-JCV antibody serostatus in Japanese MS patients with and without fingolimod.
Methods
We enrolled 128 Japanese patients with MS, in whom 64 (50%) were under fingolimod treatment at sampling, and examined the relationship between
HLA
class II alleles and anti-JCV antibody serostatus. Serum anti-JCV antibody positivity and index were measured using a second-generation two-step assay and
HLA-DRB1
and
-DPB1
alleles were genotyped.
Results
HLA-DRB1*15
carriers had a lower frequency of anti-JCV antibody positivity (57% vs 78%,
p
= 0.015), and lower antibody index (median 0.42 vs 1.97,
p
= 0.037) than non-carriers. Among patients without
HLA-DRB1*15
,
DRB1*04
carriers had a higher seropositivity rate than non-carriers (84% vs 54%,
p
= 0.030), and
DPB1*04:02
carriers had a higher anti-JCV antibody index than non-carriers (3.20 vs 1.34,
p
= 0.008) although anti-JCV antibody-positivity rates did not differ. Patients treated with fingolimod had a higher antibody index than other patients (1.46 vs 0.64,
p
= 0.039) and treatment period had a positive correlation with antibody index (
p
= 0.018). Multivariate logistic regression analysis revealed that age was positively associated, and
HLA-DRB1*15
was negatively associated with anti-JCV antibody positivity (odds ratio [OR] = 1.06,
p
= 0.006, and OR = 0.37,
p
= 0.028, respectively). Excluding
HLA-DRB1*15
-carriers,
DRB1*04
was an independent risk factor for the presence of anti-JCV antibody (OR = 5.50,
p
= 0.023).
Conclusions
HLA-DRB1*15
is associated with low anti-JCV antibody positive rate and low JCV antibody index, and in the absence of
DRB1*15
,
DRB1*04
carriers are associ...